Hauswald et al. report 97.8% actuarial 10-year PSA PFS with local control rates of 99.7% in 448 men with low-intermediate risk prostate cancer treated with HDR-BT monotherapy, 43.5 Gy in six fractions [18]. This evidence concerns the gene KLK3 and prostate cancer.